Key result
Alteplase at 3-hour and 4.5-hour thresholds fails to improve good discharge disposition.
Why the study?
Randomized controlled trials are expensive and evaluate limited populations, creating a need for techniques to estimate stroke intervention effects from observational data while minimizing confounding.
Does alteplase improve clinical outcomes at hospital discharge in patients with acute ischemic stroke when evaluated at the 3-hour and 4.5-hour treatment thresholds using regression discontinuity design?
Observational (n=21,505)
Yes
Does alteplase improve clinical outcomes at hospital discharge in patients with acute ischemic stroke when evaluated at the 3-hour and 4.5-hour treatment thresholds using regression discontinuity design?
Using regression discontinuity design on observational registry data failed to replicate the known efficacy of alteplase at 3- and 4.5-hour thresholds, highlighting methodological challenges in using this technique for stroke interventions.
Answers are grounded in this paper and cite their sources.
Null observational finding should not change alteplase practice; leaves open regression discontinuity design validity in stroke.
Randomized Controlled Trials (RCTs) are considered the gold standard for measuring the efficacy of medical interventions. However, RCTs are expensive, and use a limited population. Techniques to estimate the effects of stroke interventions from observational data that minimize confounding would be useful. We used regression discontinuity design (RDD), a technique well-established in economics, on the Get With The Guidelines-Stroke (GWTG-Stroke) data set. RDD, based on regression, measures the occurrence of a discontinuity in an outcome (e.g., home discharge) as a function of an intervention (e.g., alteplase) that becomes significantly more likely when crossing the threshold of a continuous variable (e.g., time from symptom onset). The technique assumes that patients near either side of a threshold (e.g., 2.99 and 3.01 hours from symptom onset) are indistinguishable other than the use of the treatment. We compared outcomes of patients whose estimated onset to treatment time fell on either side of the treatment threshold for three cohorts of patients in the GWTG-Stroke data set that spanned different treatment thresholds for alteplase (3 hours, 2003-2007, N=1869; 3 hours, 2009-2016, N=13,086, and 4.5 hours, 2009-2016, N=6,550). Patient demographic characteristics were overall similar across the treatment thresholds. We did not find evidence of a discontinuity in discharge disposition at any treatment threshold attributable to alteplase. Potential reasons for failing to find an effect include violation of some RDD assumptions in clinical care and large sample sizes required.
No takes yet. Share an insight, caveat, or question.
Naidech et al. (2020) conducted an observational in Acute Ischemic Stroke (n=21,505). Alteplase vs. No alteplase (patients just outside the treatment threshold) was evaluated on Good discharge disposition (Cohort B, 4.5h threshold, adjusted model) (OR 0.92, 95% CI 0.72-1.17, p=0.504). Regression discontinuity design analysis found no significant discontinuity in good discharge disposition attributable to alteplase at the 3-hour or 4.5-hour treatment thresholds.
Synapse has enriched 10 related papers. Consider them for comparative context: